View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 1, 2019

Axsome starts Phase II trial of AXS-12 to treat narcolepsy

Axsome Therapeutics has commenced the Phase II Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT) trial evaluating AXS-12 (reboxetine) for the treatment of narcolepsy.

Axsome Therapeutics has commenced the Phase II Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT) trial evaluating AXS-12 (reboxetine) for the treatment of narcolepsy.

Narcolepsy is a neurological condition that leads to dysregulation of the sleep-wake cycle. It is characterised by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, and other conditions.

The CONCERT study features a double-blind, placebo-controlled, multicentre design and is expected to enrol around 20 patients who will receive AXS-12 and placebo for three weeks.

Patients will be randomised to receive either AXS-12 followed by placebo or placebo followed by AXS-12.

The crossover trial’s efficacy endpoints will include the frequency of cataplexy attacks and identifying other symptoms of narcolepsy.

Topline data from the trial is expected to be available in the second quarter of this year.

“AXS-12 has the potential to address the key symptoms of this disorder and may not share the limitations of currently approved agents.”

Axsome Therapeutics CEO Herriot Tabuteau said: “The initiation of the CONCERT trial of AXS-12 for the treatment of narcolepsy reflects Axsome’s advancing pipeline of differentiated central nervous system CNS product candidates, and our continued commitment to developing novel medicines to improve the lives of patients living with serious and difficult-to-treat CNS disorders.

“The CONCERT trial utilises an efficient crossover design to improve signal detection and speed trial conduct.”

AXS-12 has received orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of narcolepsy.

Axsome Therapeutics Clinical Development and Medical Affairs senior vice-president Cedric O’Gorman said: “Narcolepsy is debilitating for the nearly 200,000 individuals living with this condition in the US.

“Unfortunately, treatment options for these patients are limited.

“AXS-12 has the potential to address the key symptoms of this disorder and may not share the limitations of currently approved agents.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena